Cetus, Erbamont Settle Suits: Biotechnology company Cetus...

Cetus, Erbamont Settle Suits: Biotechnology company Cetus Corp. and pharmaceuticals maker Erbamont Inc. said that litigation involved sales in the United States of the anti-cancer drug doxorubicin. One of the terms of the settlement is that Stamford, Conn.-based Erbamont issue a license to a joint venture of Emeryville, Calif.-based Cetus and Ben Venue Laboratories to use Erbamont’s patent for making ready-to-use solutions of doxorubicin. Doxorubicin, used mainly for patients undergoing chemotherapy treatment, has annual U.S. sales of more than $100 million.